• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

拉替拉韦/恩曲他滨/替诺福韦酯治疗后低乙肝表面抗体患者换用卡替拉韦/利匹韦林后乙型肝炎病毒再激活

Hepatitis B Virus Reactivation after Switch to Cabotegravir/Rilpivirine in Patient with Low Hepatitis B Surface Antibody.

出版信息

Emerg Infect Dis. 2024 Aug;30(8):1668-1671. doi: 10.3201/eid3008.240019.

DOI:10.3201/eid3008.240019
PMID:39043430
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11286062/
Abstract

A patient in Japan with HIV began antiretroviral therapy because of acute hepatitis B virus (HBV) 15 years ago, with low hepatitis B surface antibody, and experienced breakthrough HBV reactivation 4 months after switching from bictegravir/emtricitabine/tenofovir alafenamide to cabotegravir/rilpivirine. An immune escape mutation, E164V, was identified in the isolated HBV DNA.

摘要

一名日本的 HIV 患者 15 年前因急性乙型肝炎病毒 (HBV) 而开始接受抗逆转录病毒治疗，其乙型肝炎表面抗体水平较低，在从比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺转换为卡替拉韦/利匹韦林后 4 个月发生了 HBV 突破再激活。在分离的 HBV DNA 中鉴定出了一个免疫逃逸突变 E164V。

相似文献

1
Hepatitis B Virus Reactivation after Switch to Cabotegravir/Rilpivirine in Patient with Low Hepatitis B Surface Antibody.拉替拉韦/恩曲他滨/替诺福韦酯治疗后低乙肝表面抗体患者换用卡替拉韦/利匹韦林后乙型肝炎病毒再激活
Emerg Infect Dis. 2024 Aug;30(8):1668-1671. doi: 10.3201/eid3008.240019.
2
HIV-HBV vaccine escape mutant infection with loss of HBV surface antibody and persistent HBV viremia on tenofovir/emtricitabine without antiviral resistance.在未发生抗病毒耐药的情况下，使用替诺福韦/恩曲他滨治疗时，HIV-HBV 疫苗逃逸突变感染可导致 HBV 表面抗体丧失和持续性 HBV 病毒血症。
J Clin Virol. 2011 Nov;52(3):261-4. doi: 10.1016/j.jcv.2011.07.014. Epub 2011 Aug 12.
3
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial.在病毒学抑制的 HIV 成人中，长效卡替拉韦加利匹韦林转换治疗与继续固定剂量比克替拉韦、恩曲他滨和替诺福韦艾拉酚胺相比的疗效、安全性和耐受性，12 个月结果（SOLAR）：一项随机、开放标签、3b 期、非劣效性试验。
Lancet HIV. 2023 Sep;10(9):e566-e577. doi: 10.1016/S2352-3018(23)00136-4. Epub 2023 Aug 8.
4
De novo activation of HBV with escape mutations from hepatitis B surface antibody after living donor liver transplantation.活体肝移植后出现对乙型肝炎表面抗体逃逸突变的乙肝病毒重新激活。
Antivir Ther. 2011;16(4):479-87. doi: 10.3851/IMP1771.
5
Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.乙型肝炎病毒再激活与拉米夫定预防异基因干细胞移植患者的疗效。
Biol Blood Marrow Transplant. 2010 Jun;16(6):809-17. doi: 10.1016/j.bbmt.2009.12.533. Epub 2010 Jan 7.
6
Virological characteristics of occult hepatitis B virus in a North American cohort of human immunodeficiency virus type 1-positive patients on dual active anti-HBV/HIV therapy.北美一组接受双重抗乙肝病毒/艾滋病毒活性治疗的1型人类免疫缺陷病毒阳性患者中隐匿性乙型肝炎病毒的病毒学特征
J Clin Virol. 2014 Aug;60(4):347-53. doi: 10.1016/j.jcv.2014.04.021. Epub 2014 May 4.
7
Breakthrough of hepatitis B virus escape mutants after vaccination and virus reactivation.接种疫苗后乙肝病毒逃逸突变体的突破及病毒再激活
J Clin Virol. 2006 May;36 Suppl 1:S18-22. doi: 10.1016/s1386-6532(06)80004-1.
8
Reactivation of hepatitis B virus in hematopoietic stem cell transplant recipients in Japan: efficacy of nucleos(t)ide analogues for prevention and treatment.日本造血干细胞移植受者中乙型肝炎病毒再激活：核苷（酸）类似物预防和治疗的疗效
Int J Mol Sci. 2014 Nov 21;15(11):21455-67. doi: 10.3390/ijms151121455.
9
The role of anti-HBs in hepatitis B reactivation during direct-acting antiviral therapy for chronic hepatitis C.抗-HBs在慢性丙型肝炎直接抗病毒治疗期间乙肝再激活中的作用
Antivir Ther. 2018;23(6):539-542. doi: 10.3851/IMP3259.
10
Reactivation of hepatitis B virus with mutated hepatitis B surface antigen in a liver transplant recipient receiving a graft from an antibody to hepatitis B surface antigen- and antibody to hepatitis B core antigen-positive donor.在一名接受乙型肝炎表面抗原和乙型肝炎核心抗原抗体阳性供体移植的肝移植受者中，乙型肝炎病毒表面抗原突变体的再激活。
Transfusion. 2012 Sep;52(9):1999-2006. doi: 10.1111/j.1537-2995.2011.03537.x. Epub 2012 Feb 8.

引用本文的文献

1
Use of dual antiretroviral therapy in individuals with different serological patterns for hepatitis B: What are the risks? What are the clinical implications?在具有不同乙型肝炎血清学模式的个体中使用双重抗逆转录病毒疗法：风险有哪些？临床意义是什么？
HIV Med. 2025 Aug;26(8):1317-1320. doi: 10.1111/hiv.70063. Epub 2025 Jun 16.
2
To Switch or not to Switch to Long-acting Injectable Cabotegravir/Rilpivirine in PWH With Past Hepatitis B Virus (HBV) Coinfection: Which HBV Markers to Manage Risk of HBV Reactivation?对于既往合并乙型肝炎病毒（HBV）感染的艾滋病毒感染者，是否应改用长效注射用卡博特韦/利匹韦林：哪些HBV标志物可用于管理HBV再激活风险？
Open Forum Infect Dis. 2025 May 6;12(6):ofaf266. doi: 10.1093/ofid/ofaf266. eCollection 2025 Jun.
3
Hepatitis B core antibody positivity is not associated with risk of transaminase elevation following switch to dual antiretroviral therapy.乙肝核心抗体阳性与换用双联抗逆转录病毒疗法后转氨酶升高的风险无关。
AIDS. 2025 Aug 1;39(10):1344-1352. doi: 10.1097/QAD.0000000000004227. Epub 2025 Jul 1.
4
Acute Hepatitis B Infection in a Patient With Confirmed Immunity on Long-Acting Cabotegravir/Rilpivirine.使用长效卡博特韦/利匹韦林确认具有免疫力的患者发生急性乙型肝炎感染
ACG Case Rep J. 2024 Dec 27;12(1):e01575. doi: 10.14309/crj.0000000000001575. eCollection 2025 Jan.

本文引用的文献

1
Brief Report: Hepatitis B Infection or Reactivation After Switch to 2-Drug Antiretroviral Therapy: A Case Series, Literature Review, and Management Discussion.简报：转换为二联抗反转录病毒治疗后乙型肝炎感染或再激活：病例系列、文献复习和管理讨论。
J Acquir Immune Defic Syndr. 2023 Oct 1;94(2):160-164. doi: 10.1097/QAI.0000000000003239.
2
Hepatitis B seroconversion revisited: new insights into the natural history of acute hepatitis B virus (HBV) infection from quantitative and highly sensitive assays and novel biomarkers.乙型肝炎血清学转换再探讨：从定量和高灵敏度检测方法及新型生物标志物看乙型肝炎病毒（HBV）感染的自然史。
Virol J. 2021 Nov 29;18(1):235. doi: 10.1186/s12985-021-01706-w.
3
Amino Acid Polymorphism in Hepatitis B Virus Associated With Functional Cure.乙型肝炎病毒氨基酸多态性与功能性治愈相关。
Cell Mol Gastroenterol Hepatol. 2021;12(5):1583-1598. doi: 10.1016/j.jcmgh.2021.07.013. Epub 2021 Aug 2.
4
Hepatitis B reactivation after tenofovir withdrawal in an HIV-infected patient with history of cured hepatitis B virus infection and poor immunological status.一名曾治愈乙肝病毒感染且免疫状态不佳的HIV感染患者停用替诺福韦后发生乙肝再激活。
AIDS. 2021 Aug 1;35(10):1707-1708. doi: 10.1097/QAD.0000000000002941.
5
Immune-Escape Hepatitis B Virus Mutations Associated with Viral Reactivation upon Immunosuppression.免疫逃逸乙型肝炎病毒突变与免疫抑制时病毒激活相关。
Viruses. 2019 Aug 24;11(9):778. doi: 10.3390/v11090778.
6
HBV reactivation in allogeneic stem cell transplant recipients: Risk factors, outcome, and role of hepatitis B virus mutations.异基因造血干细胞移植受者中的乙肝病毒再激活：危险因素、结局及乙肝病毒突变的作用
Hepatol Commun. 2017 Nov 6;1(10):1014-1023. doi: 10.1002/hep4.1118. eCollection 2017 Dec.
7
Vaccination Against Hepatitis B Virus (HBV) in HIV-1-Infected Patients With Isolated Anti-HBV Core Antibody: The ANRS HB EP03 CISOVAC Prospective Study.对单纯抗乙肝核心抗体阳性的HIV-1感染患者进行乙肝病毒（HBV）疫苗接种：法国国家艾滋病研究机构（ANRS）HB EP03 CISOVAC前瞻性研究
J Infect Dis. 2016 Jun 1;213(11):1735-42. doi: 10.1093/infdis/jiw011. Epub 2016 Jan 14.
8
A new vaccine escape mutant of hepatitis B virus causes occult infection.一种新型乙肝病毒疫苗逃逸突变体导致隐匿性感染。
Hum Vaccin Immunother. 2015;11(2):407-10. doi: 10.4161/21645515.2014.994461.
9
CDC guidance for evaluating health-care personnel for hepatitis B virus protection and for administering postexposure management.疾病预防控制中心关于评估乙型肝炎病毒保护的卫生保健人员以及实施接触后管理的指南。
MMWR Recomm Rep. 2013 Dec 20;62(RR-10):1-19.
10
Comprehensive analysis of the prevalence of hepatitis B virus escape mutations in the major hydrophilic region of surface antigen.全面分析乙型肝炎病毒表面抗原主要亲水区域的逃逸突变的流行情况。
J Med Virol. 2012 Feb;84(2):198-206. doi: 10.1002/jmv.23183.